Poolbeg Pharma POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at 65th American Society of Hematology (‘ASH’) Annual Meeting and Exposition, to be held 9-12 December 2023 in San Diego, California.

The ASH Annual Meeting and Exposition is recognised as the world’s premier conference focussing on haematological malignancies (blood cancers) and brings together over 25,000 industry and academic attendees each year to share the latest scientific discoveries and advances in clinical care.

Poolbeg Pharma’s poster presentation will provide insight into the results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of Cytokine Release Syndrome (CRS) associated with severe influenza and cancer immunotherapies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Poolbeg Pharma’s Cathal Friel assumes role of Executive Chairman

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced a change of Board role and the Remuneration Committee’s approval of

What will cancer therapy look like in 2034?

Drugs like PARP inhibitors and chimeric antigen receptor (CAR) therapies, and advancements in artificial intelligence in drug discovery, have spurred hope for improved cancer care in the past year. Rigorous research has paved the way for a

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.